Anika Therapeutics
ANIK
118 hedge funds and large institutions have $341M invested in Anika Therapeutics in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 43 increasing their positions, 42 reducing their positions, and 20 closing their positions.
2% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 42
0.56% more ownership
Funds ownership: 93.4% → 93.96% (+0.56%)
6% less funds holding
Funds holding: 126 → 118 (-8)
19% less call options, than puts
Call options by funds: $213K | Put options by funds: $264K
29% less capital invested
Capital invested by funds: $483M → $341M (-$142M)
40% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Trigran Investments
Northbrook,
Illinois
|
+$11.1M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$8.19M |
| 3 |
State Street
Boston,
Massachusetts
|
+$3.99M |
| 4 |
Janus Henderson Group
London,
|
+$3.44M |
| 5 |
Goldman Sachs
New York
|
+$2.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$23.5M |
| 2 |
Morgan Stanley
New York
|
-$1.75M |
| 3 |
Kayne Anderson Rudnick Investment Management
Los Angeles,
California
|
-$1.66M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.15M |
| 5 |
Millennium Management
New York
|
-$1.09M |
ANIK Hedge Fund Activity: Q1 2022 in Review
118 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q1 2022, worth a combined $341M — down 29% from $483M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ANIK and 12 opened new positions — a net loss of 8 holders — while 42 trimmed existing stakes and 43 added.
The largest buyer was Trigran Investments, adding an estimated $11.1M. The largest seller was Ameriprise, cutting an estimated $23.5M.
- 118 institutional investors held Anika Therapeutics (ANIK) as of Q1 2022, down from 126 in Q4 2021.
- Funds reported $341M of Anika Therapeutics stock for Q1 2022, down 29% quarter-over-quarter.
- 12 funds opened new Anika Therapeutics positions in Q1 2022 and 20 closed out, a net change of -8 holders.
- The largest Anika Therapeutics buyer in Q1 2022 was Trigran Investments, an estimated $11.1M added.
- The largest Anika Therapeutics seller in Q1 2022 was Ameriprise, an estimated $23.5M sold.
Based on aggregated 13F filings for Q1 2022.